Antihistamine agents. Immunopharmacology презентация

type:
Type I : Anaphylactic reactions
Type II : Cytolytic reactions
Type III : Retarded reactions
B. Cell mediated (Ig-mediated):
Type IV : Delayed reactions

: Ketotifen
Mast cell stabilizers: Cromolyn, Nedocromil
β-adrenomimetics: Adrenaline, Ephedrine
Methylxanthines: Euphylline (Aminophylline)
2. Antihistamine H1 agents: Dimedrol, Diprazine, Loratadine
3. Agents eliminating generalized symptoms of immediate allergic reactions:
Adrenomimetics: Adrenaline
Methylxanthines: Euphylline, Theophylline
Ca2+ preparations: Calcium chloride, Calcium gluconate
4. Agents decreasing tissue damage: Glucocorticoids

suppressing mainly cell-mediated immunity:
Glucocorticoids,
Cyclosporin, Tacrolimus,
Cytotoxic Drugs,
Antilymphocytic serum,
Monoclonal Antibodies (Muromonab CD3), Antilymphocytic Immunoglobulin
2. Drugs decreasing tissue damage –
Glucocorticoids
NSAIDs

an agonist to H1- Receptors =>
stimulates the intracellular activity of
the Phosphatidylinositol Pathway
Binding of an agonist to H2- Receptors =>
↑the production of cAMP by Adenyl Cyclase

Histamine promotes vasodilation by causing
vascular endothelium to release Nitric Oxide (NO),
which diffuses to the vascular smooth muscle where
it stimulates cGMP production

(NON-SEDATIVE):
Loratadine (Claritin)
Terfenadine
Astemizole
Phencarol (Quifenadine)
III GENERATION (ACTIVE METABOLITES):
Telfast (Fexofenadine)
Zirtek (Cetirizine)

by reversible competitive
antagonism at the H1-receptor
▶ Antagonist effects at other receptors:
▶ M - Cholinoceptors
▶ α1 - Adrenoreceptors
▶ 5-Hydrohytryptamine (5-HT) receptors

Diprazin ▶ Dimedrol ▶ Suprastin ▶ Diazolin

on the smooth muscle of
the bronchi, GIT, uterus, and large blood vessels.
By binding to receptors, suppresses histamine-induced allergic symptoms, even though it does not prevent its release.
Central antimuscarinic actions is responsible for antivertigo, antiemetic, and antidyskinetic action.
Clinical uses:
▶ Allergy symptoms
▶ Motion sickness
▶ Parkinson’s disease
▶ Nonproductive cough
▶ Insomnia

antagonist of I generation.
It competes to histamine H1 receptor sites on the smooth muscle of the bronchi, GIT, uterus, and large blood vessels.
It has less expressed antihistamine, M-cholinoblocker and sedative effects than Dimedrol.
Clinical uses:
▶ Allergic dermatosis
▶ Allergic rhinitis
▶ Conjunctivitis
▶ Quincke’s edema
▶ Medicamental allergy
▶ Hay (pollen) fever

occasionally produced Polymorphic Ventricular Tachycardia.
The risk is increased in liver disease or when inhibitors of CYP3A4 are administered concurrently – because larger amounts of unchanged drug reach systemic circulation.
Erythromycin, Clarithromycin, Ketoconazole and Itraconazole
are the drugs precipitating their
cardiotoxicity as they block
microsomal CYP-450 enzymes.
Because of this risk,
Terfenadine has been withdrawn
by most manufactures.
Clinical use: allergic rhinitis

not block K+ channels in the heart –
does not prolong Q-T interval.

Telfast has plasma T1/2 11-16 hours and duration of action 24 hours.

- suppressing mainly
cell-mediated immunity:
1.Inhibitors of IL-2 production or action:
Cyclosporine (Sandimmune)
Tacrolimus
2.Inhibitors of cytokine gene expression:
Glucocorticoids: Prednisolone
3. Antitumor Cytotoxic Agents:
a) Alkylating agents: Cyclophosphan
b) Antimetabolites: Azathioprine, Mercaptopurine, Methotrexate
4.Blockers of the T-cell surface molecules involved in signaling - Monoclonal Antibodies: Basiliximab and Daclizumab

to suppress graft-versus-host disease
▶ to treat diseases that are believed to have autoimmune component in their pathogenesis:
● Idiopathic thrombocytopenic purpura
● Hemolytic anemia
● Glomerulonephritis
● Myasthenia gravis
● Systemic lupus erythematosus
● Rheumatoid arthritis
● Psoriasis

antibiotic with immunosuppressive activity but no effect on the acute inflammatory reaction per se.
The main action is a relatively selective inhibitory effect on IL-2 gene transcription, though an effect on
the transcription of the genes for IFN-γ and IL-3
has also been reported:
IL-2 Release and
↓ IL-2 Receptors Expression =>
↓ Clonal Proliferation of T-cells
↓ Transcription of the genes for interferon-γ
Clonal Proliferation of cytotoxic T-cells from
CD8+ precursor T-cells

Genes for
IL-2
TNF-α
IFNγ
IL-1
and many other INTERLEUKINS in both the INDUCTION and EFFECTOR PHASES of the immune response =>
Restrain the clonal proliferation of Th cells

0.5 g
● is cytotoxic only after generation of
its alkylating species, following
their hydroxylation by CYP-450.

▶ Exerts its cytotoxic effects by
covalently binding to nucleophylic groups
on various cell constituents
▶ Destroys proliferating lymphoid cells
but also appears to alkylate
some resting cells.

acts as a false substrate,
inhibits enzyme activity of dihydrofolate reductase =>
↓Tetrahydrofolic acid required for the synthesis of
Purine Bases and Thymidine =>
=> Synthesis of DNA and RNA building blocks ceases.
The effect of these antimetabolites can be reversed by administration of Folic acid.

metabolized to give
the antimetabolite 6-mercaptopurine,
a purine analogue that inhibits DNA synthesis.
▶ Both cell-mediated and antibody-mediated
immune reactions are depressed by azathioprine since
it inhibits clonal proliferation in the induction phase of
the Immune response by a cytotoxic action on dividing cells.
Clinical uses:
Control of tissue rejection in TRANSPLANT SURGERY
Autoimmune diseases: systemic lupus erythematosus,
rheumatoid arthritis.
Adverse effects:
bone marrow depression
skin eruptions, hepatotoxicity.

Th cells
They saturate the receptors and thereby:
Block T Cells Signal Transduction Events
Prevent T cells from Replication and from Activating the B cells, which are responsible for production of antibodies.

Thymogen
3. Inductor of Interferon:
Cycloferon

3 million IU, SC
amp. 100,000 IU – intranasally
Interferon - β: IFN β-1a, IFN β-1b
Interferon - γ 1b

5. Inerleukin-2
6. BCG

II. Synthetic compounds:
Levamisol (Decaris) – Tab. 50 mg and 150 mg

(Acridone-Acetic Acid)
▶ Immunomodulating
▶ Antiviral
▶ Antinflammatory effects
Clinical uses:
Viral Hepatitis
Herpetic and Cytomegalovirus Infections
Chlamidiosis
HIV-infection (AIDS, stage IIA-IIIB)
Immunodeficiency conditions

amp. 100,000 IU – intranasally
Mechanism of action:
direct antiproliferative action against tumor cells or
viral cells to inhibit replication and modulation of
host immune response by:
■ enhancing phagocytic activity of macrophages
■ augmenting specific cytotoxicity of
lymphocytes for target cells.

Renal Cell Carcinoma
T-cell Leukemia
Hepatitis B and C
Multiplied Sclerosis
Acute Respiratory Virus Infection

has been successful only in intravesical therapy for Superficial Bladder Cancer.

BCG appears to act via activation of macrophages
to make them more effective killer cells